Overview

A Study of LY2963016 in Healthy Participants

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

This study involves 2 single injections of LY2963016 and 2 single injections of Lantus. There will be at least 6 days between each injection. The study will compare LY2963016 to Lantus at two different doses. This study is approximately 10 weeks long, not including screening. Screening is required within 4 weeks of the start of the study.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin Glargine